BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22687889)

  • 1. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.
    Cuadrado-Lavín A; Salcines-Caviedes JR; Carrascosa MF; Dierssen-Sotos T; Cobo M; Campos MR; Ayestarán B; Fernández-Pousa A; González-Colominas E; Aresti-Zárate S; Hernández M; Pascual EL
    J Antimicrob Chemother; 2012 Sep; 67(9):2254-9. PubMed ID: 22687889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
    Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
    Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
    Molina-Infante J; Perez-Gallardo B; Fernandez-Bermejo M; Hernandez-Alonso M; Vinagre G; Dueñas C; Mateos-Rodriguez JM; Gonzalez-Garcia G; Abadia EG; Gisbert JP
    Aliment Pharmacol Ther; 2010 May; 31(10):1077-84. PubMed ID: 20180787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
    Nseir W; Diab H; Mahamid M; Abu-Elheja O; Samara M; Abid A; Mograbi J
    Aliment Pharmacol Ther; 2012 Aug; 36(3):231-8. PubMed ID: 22646167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
    Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
    Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
    Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
    Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
    Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
    Zullo A; Scaccianoce G; De Francesco V; Ruggiero V; D'Ambrosio P; Castorani L; Bonfrate L; Vannella L; Hassan C; Portincasa P
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):647-50. PubMed ID: 23747131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
    Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
    Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
    Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X;
    J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study].
    Cheng H; Hu FL; Zhang GX; Shi RH; Du YQ; Li ZS; Han W; Li YQ; Wu QD; Qian KD
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):79-82. PubMed ID: 20356486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
    Polat Z; Kadayifci A; Kantarcioglu M; Ozcan A; Emer O; Uygun A
    Eur J Intern Med; 2012 Mar; 23(2):165-8. PubMed ID: 22284248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
    Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
    J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
    Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.